A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer

Cancer Research

Volumn 69, Issue 16, 2009, Pages 6685-6693

  Min, Chengyin ^a   Yu, Ziyang ^a   Kirsch, Kathrin H ^a   Zhao, Yingshe ^a   Vora, Siddharth R ^b   Trackman, Philip C ^b   Spicer, Douglas B ^d   Rosenberg, Lynn ^c   Palmer, Julie R ^c   Sonenshein, Gail E ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

^c BOSTON UNIVERSITY   (United States)

^d Maine Medical Center Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLYCINE; PROTEIN LYSINE 6 OXIDASE; RAS PROTEIN;

AFRICAN AMERICAN; ALLELE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DATA BASE; GENE EXPRESSION; GENE FUNCTION; GENETIC POLYMORPHISM; HAPLOTYPE MAP; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RISK; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; XENOGRAFT;

ADULT; AGED; AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CELLS, CULTURED; FEMALE; HUMANS; MICE; MICE, NUDE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN PRECURSORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-LYSINE 6-OXIDASE; SEQUENCE HOMOLOGY, AMINO ACID; TRANSPLANTATION, HETEROLOGOUS; YOUNG ADULT;

EID: 69249094920     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4818     Document Type: Article

References (48)

1. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 2003;88:660-72.
2. Kagan HM, Trackman PC. Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol 1991;5:206-10.
3. Contente S, Kenyon K, Rimoldi D, Friedman RM. Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science 1990;249: 796-8.
4. Kenyon K, Contente S, Trackman PC, Tang J, Kagan HM, Friedman RM. Lysyl oxidase and rrg messenger RNA. Science 1991;253:802.
5. Bouez C, Reynaud C, Noblesse E, et al. The lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model. Clin Cancer Res 2006;12:1463-9.
6. He J, Tang HJ, Wang YY, et al. [Expression of lysyl oxidase gene in upper digestive tract carcinomas and its clinical significance]. Ai Zheng 2002;21:671-4.
7. Kaneda A, Wakazono K, Tsukamoto T, et al. Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res 2004;64:6410-5.
8. Rost T, Pyritz V, Rathcke IO, Gorogh T, Dunne AA, Werner JA. Reduction of LOX- and LOXL2-mRNA expression in head and neck squamous cell carcinomas. Anticancer Res 2003;23:1565-73.
9. Shames DS, Girard L, Gao B, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 2006;3:e486.
10. Wu M, Min C, Wang X, et al. Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells. Cancer Res 2007;67:6278-85.
11. Jeay S, Pianetti S, Kagan HM, Sonenshein GE. Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-κB. Mol Cell Biol 2003;23: 2251-63.
12. Trackman PC, Bedell-Hogan D, Tang J, Kagan HM. Post-translational glycosylation and proteolytic processing of a lysyl oxidase precursor. J Biol Chem 1992;267: 8666-71.
13. Palamakumbura AH, Jeay S, Guo Y, et al. The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. J Biol Chem 2004;279: 40593-600.
14. Min C, Kirsch KH, Zhao Y, et al. The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer. Cancer Res 2007;67:1105-12.
15. Zhao Y, Min C, Vora S, Trackman PC, Sonenshein GE, Kirsch KH. The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of FAK and p130CAS in breast cancer cells. J Biol Chem 2009;284:1385-93.
16. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002; 31:33-6.
17. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
18. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 2005;97: 439-48.
19. Wang X, Belguise K, Kersual N, et al. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 2007;9:470-8.
20. Hurtado PA, Vora S, Sume SS, et al. Lysyl oxidase propeptide inhibits smooth muscle cell signaling and proliferation. Biochem Biophys Res Commun 2008;366: 156-61.
21. Cozier YC, Palmer JR, Rosenberg L. Comparison of methods for collection of DNA samples by mail in the Black Women's Health Study. Ann Epidemiol 2004;14: 117-22.
22. Rosner B. Fundamentals of biostatistics. 5th ed. Pacific Grove (CA): Duxbury Thomson Learning; 2000.
23. Freidlin B, Zheng G, Li Z, Gastwirth JL. Trend tests for case-control studies of genetic markers: power, sample size and robustness. Hum Hered 2002;53:146-52.
24. Seve S, Decitre M, Gleyzal C, et al. Expression analysis of recombinant lysyl oxidase (LOX) in myofibroblastlike cells. Connect Tissue Res 2002;43:613-9.
25. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002;21:1159-66.
26. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006;440:1222-6.
27. Kirschmann DA, Seftor EA, Fong SF, et al. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 2002;62:4478-83.
28. Payne SL, Fogelgren B, Hess AR, et al. Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res 2005;65:11429-36.
29. van de Vijver MJ, He YD, van't Veer LJ, et al. A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
30. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003;100:10393-8.
31. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006;24:4236-44.
32. Futreal PA, Kasprzyk A, Birney E, Mullikin JC, Wooster R, Stratton MR. Cancer and genomics. Nature 2001;409:850-2.
33. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
34. Csiszar K, Fong SF, Ujfalusi A, et al. Somatic mutations of the lysyl oxidase gene on chromosome 5q23.1 in colorectal tumors. Int J Cancer 2002;97:636-42.
35. Hamalainen ER, Kemppainen R, Kuivaniemi H, et al. Quantitative polymerase chain reaction of lysyl oxidase mRNA in malignantly transformed human cell lines demonstrates that their low lysyl oxidase activity is due to low quantities of its mRNA and low levels of transcription of the respective gene. J Biol Chem 1995; 270:21590-3.
36. Mendes-da-Silva P, Moreira A, Duro-da-Costa J, Matias D, Monteiro C. Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma. Mol Pathol 2000;53:184-7.
37. Wang ZC, Lin M, Wei LJ, et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 2004; 64:64-71.
38. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3: 415-28.
39. Giampuzzi M, Botti G, Cilli M, et al. Downregulation of lysyl oxidase-induced tumorigenic transformation in NRK-49F cells characterized by constitutive activation of ras proto-oncogene. J Biol Chem 2001;276:29226-32.
40. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001;358: 1389-99.
41. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet 2008;40: 17-22.
42. Easton DF, Pooley KA, Dunning AM, et al. Genomewide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-93.
43. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-4.
44. Sahlin P, Windh P, Lauritzen C, Emanuelsson M, Gronberg H, Stenman G. Women with Saethre-Chotzen syndrome are at increased risk of breast cancer. Genes Chromosomes Cancer 2007;46:656-60.
45. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 2008;14:8000-9.
46. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
47. Garcia-Closas M, Hall P, Nevanlinna H, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008;4:e1000054.
48. Allred DC, Brown P, Medina D. The origins of estrogen receptor a-positive and estrogen receptor a-negative human breast cancer. Breast Cancer Res 2004;6:240-5.